Medexus Pharmaceuticals (TSE:MDP) Given a C$8.25 Price Target by Leede Financial Analysts

Medexus Pharmaceuticals (TSE:MDP) received a C$8.25 target price from investment analysts at Leede Financial in a report released on Monday, BayStreet.CA reports. The firm presently has a “speculative buy” rating on the stock. Leede Financial’s price objective would indicate a potential upside of 208.99% from the company’s current price.

Several other analysts also recently weighed in on MDP. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, June 26th. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus boosted their price target on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

TSE MDP remained flat at C$2.67 on Monday. The company’s stock had a trading volume of 3,001 shares, compared to its average volume of 43,874. The company’s 50-day moving average is C$2.45 and its 200-day moving average is C$1.98. Medexus Pharmaceuticals has a one year low of C$1.44 and a one year high of C$3.39. The firm has a market capitalization of C$65.50 million, a PE ratio of 53.40 and a beta of 1.95.

Medexus Pharmaceuticals (TSE:MDP) last released its quarterly earnings results on Wednesday, August 7th. The company reported C$0.11 EPS for the quarter, topping the consensus estimate of C$0.04 by C$0.07. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%. The firm had revenue of C$37.33 million for the quarter, compared to analyst estimates of C$36.95 million. On average, equities research analysts anticipate that Medexus Pharmaceuticals will post 0.1626066 EPS for the current year.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.